The Medical Letter on Drugs and Therapeutics
Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The antibiotic aztreonam is now available as an inhalation solution (Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa. It is the second inhaled antibiotic to be FDA-approved for this indication in CF patients; the aminoglycoside tobramycin (Tobi) was the first. Inhaled antibiotics offer the advantage of high airway concentrations while minimizing systemic side effects.1

CLINICAL STUDIES — In a double-blind trial, 211 CF patients were randomized to inhalation of aztreonam 75 mg or placebo for 28 days. The primary endpoint, which was the time to a need for additional inhaled or intravenous antipseudomonal antibiotics, was reached at 92 days with aztreonam and at 71 days with placebo. The prespecifed secondary outcomes of lung function and respiratory symptoms also improved ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis
Article code: 1344c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian